Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lykos Therapeutics
Biotech
'Several concerning observations': FDA sheds light on rejections
The FDA’s ongoing effort to establish a culture of “radical transparency” saw the agency publish another haul of complete response letters yesterday.
James Waldron
Sep 5, 2025 10:45am
Lykos still plotting path to approval for rejected MDMA therapy
Jan 17, 2025 9:00am
Lykos accepts FDA view that MDMA med needs new trial for approval
Oct 21, 2024 8:31am
Biopharma layoff rate stabilizes in Q3: Fierce Biotech analysis
Oct 4, 2024 3:50pm
BMS vet answers Foghorn’s call for CBO—Chutes & Ladders
Sep 6, 2024 8:30am
After FDA rejection and layoffs, Lykos' CEO is leaving
Sep 5, 2024 1:39pm